سعر نوزيترون 0.075مجم/1.5مل فيال 2022

Nausetron 0.075 mg/1.5 ml vial for IV use (Eva pharma, Egypt): palonosetron solution for intravenous injection/infusion, 0.075 mg in 1.5 ml (0.05 mg/ml).

• Prevention of acute and delayed nausea and vomiting associated with MEC; acute nausea and vomiting with HEC (US IV palonosetron label).Population: AdultsDailyMed (U.S. National Library of Medicine)
• Prevention of postoperative nausea and vomiting for up to 24 hours (US IV label; efficacy beyond 24 h not demonstrated).Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common in CINV (≥5%): headache and constipation. In PONV (≥2%): QT prolongation, bradycardia, headache, constipation.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to palonosetron or any of its components.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity reactions including anaphylaxis reported; serotonin syndrome with concomitant serotonergic drugs — monitor and discontinue if symptoms occur.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Serotonergic drugs (e.g. SSRIs, SNRIs)ModerateSerotonin syndrome reported with 5-HT3 antagonists plus serotonergic drugs; monitor and discontinue if it occurs.DailyMed (U.S. National Library of Medicine)

• No available data on palonosetron HCl use in pregnant women to inform a drug-associated risk; animal studies did not show embryo-fetal developmental effects at high multiples of the human IV dose.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk; consider developmental/health benefits of breastfeeding along with clinical need and potential adverse effects.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Palonosetron: Blocks serotonin 5-HT3 receptors on vagal afferents and in the chemoreceptor trigger zone.